Research programme: cyclo-oxygenase-2 inhibitors - Esteve

Drug Profile

Research programme: cyclo-oxygenase-2 inhibitors - Esteve

Alternative Names: COX-2 inhibitors research programme - Esteve; Cyclo-oxygenase-2 inhibitors research programme - Esteve; Research programme: COX-2 inhibitors - Esteve

Latest Information Update: 18 Jul 2006

Price : $50

At a glance

  • Originator Esteve
  • Class
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Osteoarthritis; Pain

Most Recent Events

  • 18 Jul 2006 No development reported - Preclinical for Cancer in Spain (unspecified route)
  • 18 Jul 2006 No development reported - Preclinical for Pain in Spain (unspecified route)
  • 18 Jul 2006 No development reported - Preclinical for Osteoarthritis in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top